{"analyses":[{"ciLowerLimit":"0.90","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.88","estimateComment":"Hazard ratio is for Rituximab Retreatment Arm/Rituximab Scheduled Arm in follicular patients.","groupDescription":"The primary analysis is to compare the time to rituximab failure (TTRF) between the retreatment arm and the scheduled arm in follicular patients.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.33","paramType":"Hazard Ratio (HR)","paramValue":"1.3","statisticalMethod":"Log Rank"},{"ciLowerLimit":"1.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.19","estimateComment":"Hazard ratio is for Rituximab Retreatment Arm/Rituximab Scheduled Arm in non-follicular patients.","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.012","paramType":"Hazard Ratio (HR)","paramValue":"2.75","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.09","upperLimit":"4.93","value":"3.92"},{"groupId":"OG001","lowerLimit":"3.53","upperLimit":"4.98","value":"4.32"},{"comment":"Upper boundary has not been reached","groupId":"OG002","lowerLimit":"1.07","upperLimit":"NA","value":"1.39"},{"comment":"Upper boundary has not been reached","groupId":"OG003","lowerLimit":"2.46","upperLimit":"NA","value":"4.83"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"146"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"29"}],"units":"Participants"}],"description":"TTRF is defined as the time from randomization until any one of the following criteria are met, and censored at last disease assessment for cases who have not experienced failure (with the cut-off date for final analysis of 11/1/2011): 1. No response (partial response (PR) or complete response (CR)) to rituximab retreatment (Arm A treatment). 2. Time to progression \\< 26 weeks from day 1 of most recent rituximab treatment. 3. Initiation of alternative therapy. 4. Inability to complete protocol therapy (due to adverse events, patient preference, or any other reason, including death).","dispersionType":"95% Confidence Interval","groups":[{"description":"Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG000","title":"Rituximab Retreatment: Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG001","title":"Rituximab Scheduled: Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG002","title":"Rituximab Retreatment: Non-Follicular Patients"},{"description":"Following induction rituximab, patients who were randomized to this arm received a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity. Follicular and non-follicular patients were analyzed separately per protocol.","id":"OG003","title":"Rituximab Scheduled: Non-Follicular Patients"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who were randomized to one of the two arms for maintenance therapy.","reportingStatus":"POSTED","timeFrame":"Assessed (by restaging CT scans) 26 weeks ± 2 weeks from each rituximab treatment (including induction), counting the first rituximab dose as Day 1, until rituximab failure observed or July 17, 2013, whichever occurred first.","title":"Time to Rituximab Failure (TTRF)","type":"PRIMARY","unitOfMeasure":"years"}